Sandra K Kostyk

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4010157/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Age of onset and behavioral manifestations in Huntington's disease: An <scp>Enrollâ€HD</scp> cohort analysis. Clinical Genetics, 2021, 99, 133-142.	1.0	9
2	Carpet Neurons and the Bottom Line. Neurology, 2021, 97, 641-641.	1.5	0
3	Immediate effects of treadmill walking in individuals with Lewy body dementia and Huntington's disease. Gait and Posture, 2021, 86, 186-191.	0.6	4
4	F41â€The proof-hd phase 3 study: pridopidine's outcome on function in huntington disease (PROOF). , 2021, , .		1
5	Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients—A Randomized Phase 2 Clinical Trial. Journal of Clinical Medicine, 2020, 9, 3682.	1.0	15
6	Data-driven evolution of neurosurgical gene therapy delivery in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1210-1218.	0.9	16
7	Genotyping single nucleotide polymorphisms for allele-selective therapy in Huntington disease. Neurology: Genetics, 2020, 6, e430.	0.9	6
8	The Step Test Evaluation of Performance on Stairs (STEPS): Validation and reliability in a neurological disorder. PLoS ONE, 2019, 14, e0213698.	1.1	4
9	Pond neurons. Neurology, 2018, 90, 90-90.	1.5	1
10	Quantitative biomechanical assessment of trunk control in Huntington's disease reveals more impairment in static than dynamic tasks. Journal of the Neurological Sciences, 2017, 376, 29-34.	0.3	18
11	A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. Neurology, 2017, 88, 152-159.	1.5	104
12	Safety of Converting From Tetrabenazine to Deutetrabenazine for the Treatment of Chorea. JAMA Neurology, 2017, 74, 977.	4.5	209
13	Cognitive Dysfunction Contributes to Mobility Impairments in Huntington's Disease. Journal of Huntington's Disease, 2017, 6, 363-370.	0.9	19
14	Long-term follow-up of a randomized AAV2-GAD gene therapy trial for Parkinson's disease. JCI Insight, 2017, 2, e90133.	2.3	74
15	Paired Studies Comparing Clinical Profiles of Lewy Body Dementia with Alzheimer's and Parkinson's Diseases. Journal of Alzheimer's Disease, 2016, 54, 995-1004.	1.2	23
16	Motor performance differentiates individuals with Lewy body dementia, Parkinson's and Alzheimer's disease. Gait and Posture, 2016, 50, 1-7.	0.6	69
17	Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS). JAMA Neurology, 2016, 73, 102.	4.5	38
18	Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2015, 14, 39-47.	4.9	112

Sandra K Kostyk

#	Article	IF	CITATIONS
19	Impact of tetrabenazine on gait and functional mobility in individuals with Huntington's disease. Journal of the Neurological Sciences, 2014, 347, 219-223.	0.3	11
20	A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease. JAMA Neurology, 2014, 71, 543.	4.5	312
21	Clinimetric properties of the Tinetti Mobility Test, Four Square Step Test, Activities-specific Balance Confidence Scale, and spatiotemporal gait measures in individuals with Huntington's disease. Gait and Posture, 2014, 40, 647-651.	0.6	28
22	A randomized, doubleâ€blind, placebo ontrolled trial of pridopidine in Huntington's disease. Movement Disorders, 2013, 28, 1407-1415.	2.2	111
23	Assistive devices alter gait patterns in Parkinson disease: Advantages of the four-wheeled walker. Gait and Posture, 2013, 38, 20-24.	0.6	43
24	Video game play (Dance Dance Revolution) as a potential exercise therapy in Huntington's disease: a controlled clinical trial. Clinical Rehabilitation, 2013, 27, 972-982.	1.0	65
25	The Impact of Different Types of Assistive Devices on Gait Measures and Safety in Huntington's Disease. PLoS ONE, 2012, 7, e30903.	1.1	40
26	AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurology, The, 2011, 10, 309-319.	4.9	582
27	Progranulin expression is upregulated after spinal contusion in mice. Acta Neuropathologica, 2010, 119, 123-133.	3.9	63
28	Fall risk assessment using the Tinetti mobility test in individuals with Huntington's disease. Movement Disorders, 2010, 25, 2838-2844.	2.2	54
29	Robust axonal growth and a blunted macrophage response are associated with impaired functional recovery after spinal cord injury in the MRL/MpJ mouse. Neuroscience, 2008, 156, 498-514.	1.1	20
30	Randomized Controlled Trial of Ethyl-Eicosapentaenoic Acid in Huntington Disease. Archives of Neurology, 2008, 65, 1582-9.	4.9	71
31	Dopaminergic Modulation of Semantic Priming in Parkinson Disease. Cognitive and Behavioral Neurology, 2008, 21, 134-137.	0.5	17
32	Reliability and Validity of the Tinetti Mobility Test for Individuals With Parkinson Disease. Physical Therapy, 2007, 87, 1369-1378.	1.1	172
33	Symptomatic gallstones in patients with spinal cord injury. Journal of Gastrointestinal Surgery, 2000, 4, 642-647.	0.9	7
34	Referred phantom sensations and cortical reorganization after spinal cord injury in humans. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 14703-14708.	3.3	122
35	The Effects of Collagen-Based Implants on Early Healing of the Adult Rat Spinal Cord. Tissue Engineering, 1997, 3, 309-317.	4.9	26
36	Unusual expression of the HU paraneoplastic antigen in the visual system. NeuroReport, 1996, 7, 1549-1552.	0.6	12

Sandra K Kostyk

#	Article	IF	CITATIONS
37	Regulation of neural cell survival and differentiation by peptide growth factors. Current Opinion in Cell Biology, 1990, 2, 1050-1057.	2.6	26
38	Substance P immunoreactive astrocytes are present in multiple sclerosis plaques. Brain Research, 1989, 504, 284-288.	1.1	55
39	Neuronal organization underlying visually elicited prey orienting in the frog—II. Anatomical studies on the laterality of central projections. Neuroscience, 1987, 21, 57-82.	1.1	64
40	Neuronal organization underlying visually elicited prey orienting in the frog—III. Evidence for the existence of an uncrossed descending tectofugal pathway. Neuroscience, 1987, 21, 83-96.	1.1	54
41	Neuronal organization underlying visually elicited prey orienting in the frog—I. Effects of various unilateral lesions. Neuroscience, 1987, 21, 41-55.	1.1	70
42	Prey orienting in frogs: Accounting for variations in output with stimulus distance. Journal of Comparative Physiology A: Neuroethology, Sensory, Neural, and Behavioral Physiology, 1985, 156, 775-785.	0.7	19
43	Frog Prey Capture Behavior: Between Sensory Maps and Directed Motor Output. , 1983, , 331-347.		27
44	Visual orienting deficits in frogs with various unilateral lesions. Behavioural Brain Research, 1982, 6, 379-388.	1.2	180
45	Orienting behavior of juvenile frogs with both a pre-metamorphically rotated and a normal eye. Behavioural Brain Research, 1982, 4, 55-62.	1.2	4
46	The potential binocular field and its tectal representation inrana pipiens. Journal of Comparative Neurology, 1980, 190, 175-185.	0.9	40
47	Ovulation in Immature Rats in Relation to the Time and Dose of Injected Human Chorionic Conadotropin or Pregnant Mare Serum Conadotropin, Biology of Reproduction, 1978, 19, 1102-1107	1.2	12